This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
by Zacks Equity Research
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.
Ultragenyx Gets FDA Nod for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval for the label expansion of Crysvita into tumor-induced osteomalacia.
Editas (EDIT) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
Editas (EDIT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Alnylam???s Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
by Zacks Equity Research
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Affimed (AFMD) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
by Zacks Equity Research
bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
NeuBase (NBSE) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
by Zacks Equity Research
Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.
Mustang Bio (MBIO) Jumps: Stock Rises 8.2%
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Immunic Gets FDA Allowance for Phase II Coronavirus Study
by Zacks Equity Research
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Alexion (ALXN) Catches Eye: Stock Jumps 7.8%
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 6.3%
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
by Zacks.com
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Why Akcea (AKCA) Stock Might be a Great Pick
by Zacks Equity Research
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akcea Therapeutics (AKCA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for March 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for March 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe
by Zacks Equity Research
Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.